Friday, December 17, 2010

Polluted air increases obesity risk in young animals

ScienceDaily (Dec. 3, 2010) ? Exposure to polluted air early in life led to an accumulation of abdominal fat and insulin resistance in mice even if they ate a normal diet, according to new research.

Animals exposed to the fine-particulate air pollution had larger and more fat cells in their abdominal area and higher blood sugar levels than did animals eating the same diet but breathing clean air.

Researchers exposed the mice to the polluted air for six hours a day, five days a week for 10 weeks beginning when the animals were 3 weeks old. This time frame roughly matches the toddler years to late adolescence in humans.

The exposure levels for the animals subjected to polluted air resemble the fine-particulate pollution that can be found in urban areas in the United States.

"This is one of the first, if not the first, study to show that these fine particulates directly cause inflammation and changes in fat cells, both of which increase the risk for Type 2 diabetes," said Qinghua Sun, an associate professor of environmental health sciences at Ohio State University and lead author of the study.

The research appears in the December issue of the journal Arteriosclerosis, Thrombosis, and Vascular Biology.

Sun and colleagues fed the mice with either a normal diet or a high-fat diet and exposed them to either filtered air or air containing at least seven times more fine particulates than the ambient air in Columbus, Ohio. On average, the ambient air contained 15.8 micrograms of fine particles per cubic meter, compared to 111 micrograms per cubic meter in the concentrated air to which the mice were exposed.

According to the U.S. Environmental Protection Agency, roughly one out of every three people in the United States is at a higher risk of experiencing health effects related to the presence of polluted air. Because of their tiny size -- 2.5 micrometers or smaller in diameter, or about 1/30th of the average width of a human hair -- these particles could reach deep areas of the lungs and other organs in the body.

For this study, researchers obtained baseline measures of the mice for their weight, blood sugar and body fat at the start of the experiment. After exposing the animals to polluted or filtered air for 10 weeks, researchers analyzed the mice for a number of risk factors associated with obesity and insulin resistance, the hallmark of Type 2 diabetes.

As expected, mice on the high-fat diet gained much more weight than those on the normal diet. But mice exposed to polluted air and eating the normal diet had more significant elevations in glucose -- sugar in their blood -- than did normal-diet mice that breathed clean air. They also showed more signs of insulin resistance based on an index that measures both sugar and insulin in the blood at the same time.

Insulin resistance results when the presence of insulin does not initiate the transfer of glucose from the blood into the tissues, where it is used for energy.

Mice exposed to pollution -- regardless of which diet they ate --also had higher blood levels of tumor necrosis factor-alpha, a protein involved in systemic inflammation, than did mice breathing clean air.

In addition, both abdominal and subcutaneous (under the skin) types of fat were increased with exposure to pollution in mice, even in animals that ate the normal diet. Mice eating a high-fat diet also had more fat, but their exposure to polluted air did not exacerbate those effects.

"These findings suggest that fine particulate pollution exposure alone, in the presence of a normal diet, may lead to an increase in fat cell size and number, and also have a proinflammatory effect," said Sanjay Rajagopalan, senior author of the study and the John W. Wolfe Professor of Cardiovascular Medicine at Ohio State.

Fat cell size and quantity is important in many diseases because the tissue made up of fat cells begins to secrete molecules that send out complex signals. This process can lead to inflammation and, in turn, to insulin resistance or diabetes, as well as other disease conditions. Abdominal, or visceral, fat in particular is closely associated with the development of cardiovascular disease.

The scientists do not yet know whether these effects would be sustained over adult life if air quality circumstances were changed, or if they are otherwise reversible.

"We really wanted to see how this air pollution affects obesity with this early life exposure," Sun said. "In a real-world scenario, it would be very difficult to escape from the pervasive influence of dirty air, an influence that begins very early on in life."

A To explore the physiological mechanism behind the pollution's effects on fat cells and inflammation, the researchers tested the same exposure levels in mice that had been genetically modified so they don't carry a gene called p47phox. This gene is a subunit of an enzyme linked to free radicals that lead to the accumulation of inflammatory cells in artery walls and plaque, known as atherosclerosis.

Mice without this gene that were exposed to pollution did not show most of the effects of that exposure that normal mice showed, Sun said.

"When you knock out p47phox, it pretty much alleviates the effects of air pollution," he said. "What this gives us is a potential for future therapeutic options that might target this gene."

More research would be required to further define this mechanism, he noted.

These same researchers do plan to continue studying the effects of fine particulate pollution on health, and have designed a study in humans that will take place in Beijing, China. The project, led by Rajagopalan, will test the effects of air pollution on metabolic syndrome and insulin resistance in patients. Participants will wear personal monitors to gauge their exposure to pollution.

This research is supported by the National Institutes of Health and the Diabetes Action Research and Education Foundation.

Additional co-authors of the paper are Xiaohua Xu, Zubin Yavar and Matt Verdin of the Division of Environmental Health Sciences in Ohio State's College of Public Health; Zhekang Ying, Georgeta Mihai, Thomas Kampfrath and Aixia Wang of Ohio State's Davis Heart and Lung Research Institute; and Mianhua Zhong, Morton Lippmann and Lung-Chi Chen of New York University School of Medicine.

Disclaimer: This article is not intended to provide medical advice, diagnosis or treatment. Views expressed here do not necessarily reflect those of ScienceDaily or its staff.

Story Source:

The above story is reprinted (with editorial adaptations by ScienceDaily staff) from materials provided by Ohio State University. The original article was written by Emily Caldwell.

Journal Reference:

X. Xu, Z. Yavar, M. Verdin, Z. Ying, G. Mihai, T. Kampfrath, A. Wang, M. Zhong, M. Lippmann, L.-C. Chen, S. Rajagopalan, Q. Sun. Effect of Early Particulate Air Pollution Exposure on Obesity in Mice: Role of p47phox. Arteriosclerosis, Thrombosis, and Vascular Biology, 2010; 30 (12): 2518 DOI: 10.1161/ATVBAHA.110.215350

Note: If no author is given, the source is cited instead.


View the original article here

Glucose-Responsive Insulin Advances Toward Clinical Development


Main Category: Diabetes
Also Included In: Pharma Industry / Biotech Industry
Article Date: 07 Dec 2010 - 0:00 PST window.fbAsyncInit = function() { FB.init({ appId: 'aa16a4bf93f23f07eb33109d5f1134d3', status: true, cookie: true, xfbml: true, channelUrl: 'http://www.medicalnewstoday.com/scripts/facebooklike.html'}); }; (function() { var e = document.createElement('script'); e.async = true; e.src = document.location.protocol + '//connect.facebook.net/en_US/all.js'; document.getElementById('fb-root').appendChild(e); }()); email icon email to a friend ? printer icon printer friendly ? write icon opinions ?
4 starsnot yet rated
Pharmaceutical company, Merck & Co., Inc. has announced that it will acquire SmartCells, Inc., a private biotech developing a glucose-responsive insulin whose proof-of-concept preclinical trials were partially funded by the Juvenile Diabetes Research Foundation (JDRF). SmartCells' product for the treatment of diabetes is designed to be a once-a-day injection that will maintain continuous, tight control of blood glucose levels while reducing the risk of hypoglycemia - like the pancreas does automatically in the absence of diabetes.

"This is exciting news for the diabetes research field and for JDRF. We believe this novel technology may lead to a practical solution to the real needs of people with diabetes," said Dr. Richard Insel, Chief Scientific Officer at JDRF. "We are pleased to see that SmartCells' technology has attracted the support of a leading pharmaceutical company that has the capacity to translate this opportunity to patients," added Insel.

JDRF funds critical gaps in the type 1 diabetes drug and device pipeline by supporting discovery and proof-of-concept research for innovative ideas that might otherwise remain unexplored. This is the sixth time that an early-stage product supported by JDRF has attracted the attention of industry, which has the expertise and resources to bring novel technologies to patients as quickly as possible. From 2008 to 2010, JDRF provided significant financial support - a total of over $1.5 million in funding - to the early-stage development of SmartInsulin™.

"A measure of JDRF's success is identifying and advancing promising research that may benefit people with type 1 diabetes," says Dr. Karin Hehenberger, Senior Vice President of Strategic Alliances at JDRF. "Merck's acquisition of SmartCells is an example of exactly this. A potentially transformational innovation has now been taken up by a large pharmaceutical company thanks in part to our support. This acquisition adds important financial and drug development capabilities to this promising glucose-responsive insulin."

Biotechnology companies often face challenges in advancing novel therapies beyond the initial stages of research. Through its Industry Discovery and Development Program (IDDP), JDRF identifies unique technologies that would not be advanced otherwise and partners with companies to test concepts and bring better treatments and therapeutics leading to a cure to patients faster. To date, JDRF has funded type 1 diabetes projects at 30 companies, committing approximately $72 million in research funding.

"Our funding to SmartCells was an important step in what has become the JDRF Insulin Initiative," noted Dr Sanjoy Dutta, Director of Glucose Control research at JDRF. "We are focused on supporting an effort towards the development of faster-acting insulins, other glucose-responsive insulins and novel therapies that will help people with diabetes maintain glucose control with less effort."

Diabetes is a large and growing challenge with as many as 3 million people in the United States living with type 1 diabetes and another 30,000 are newly-diagnosed each year. A recent CDC modeling report indicated that as many as one in three individuals could have diabetes, either type 1 or 2, by the year 2050. Better treatments are desperately needed to help people live better with the disease today as research continues toward an eventual cure.

Source:
Joana Casas
Juvenile Diabetes Research Foundation International

Please rate this article:
(Hover over the stars
then click to rate) Bookmark and Share

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.

All opinions are moderated before being added.

Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:






View the original article here

Diabetes Cuts Years off Life Span of Americans

Study Shows Sharp Increase in Percentage of Adults With Diabetesclose-up of fat man in blue shirt

Dec. 1, 2010 -- Diabetes cuts about 8.5 years off the life span of the average 50-year-old compared to a 50-year-old without diabetes, new research indicates.

The study also shows that older adults with diabetes have a lower life expectancy at every age compared to people who do not have the disease. For example, researchers say, the difference at age 60 is 5.4 years; it’s one year by 90.

The findings come from a new report commissioned by the National Academy on an Aging Society and was supported by Sanofi-aventis U.S., a pharmaceutical company. It was based on data provided by the Health and Retirement Study, a survey of more than 20,000 Americans over age 50 done every two years by the University of Michigan.

“Given the rise in diabetes among boomers and seniors, these findings are alarming,” Greg O’Neill, PhD, director of the National Academy on an Aging Society, says in a news release. “They paint a stark picture of the impact of diabetes and its complications on healthy aging.”

The study shows a significant increase over the past decade in the percentage of adults over age 50 with diabetes, from 11% of non-Hispanic whites in 1998 to 18% in 2008, coinciding with an alarming obesity epidemic affecting most population groups.

The increase among adult non-Hispanic blacks has been even more alarming, from 22% to 32% in the past 10 years, study researchers say.

Compared to older adults without diabetes, patients with the disease are less likely to be employed and more likely to have other health problems, such as heart disease, depression, and disabilities that get in the way of normal life activities, the researchers say.

Scott M. Lynch, PhD, of Princeton University’s Office of Population Research, analyzed data on more than 20,000 adults over the age of 50. The study, described as a “profile,” was written by Nancy Maddox, MPH, a co-founder of Maren Enterprises, a consulting firm specializing in technical and promotional writing in the field of public health.

The researchers say at least 7.8% of the U.S. population, or some 23.6 million people, have diabetes, including 5.7 million who don’t know they do.

The study also shows that:

23.1% of people 60 and older, or 12.2 million people, have diabetes.By 2034, this number will increase to 44.1 million.By the same year, 14.6 million people who are Medicare-eligible will have the disease.Annual diabetes-related spending is expected to reach $336 billion in 2034, which is almost three times the amount spent in 2009.In 2007, diagnosed diabetes cost the U.S. an estimated $116 billion in direct medical costs and $58 billion in reduced productivity.People with diabetes are responsible for about 20% of U.S. health care expenditures.By 2025, more than half of people with diabetes will be 65 and older, and if this trend continues, it will become primarily a geriatric disease. In 2000, people 65 and older accounted for 40% of U.S. diabetes cases.The prevalence of diabetes is projected to more than double between 2005 and 2050 for U.S. residents 20 to 64 and increase 220% for people between 65 and 74. For people 75 and older the prevalence is expected to increase 449%.Diabetes is more common among non-whites; African-Americans are more likely to develop the disease than either whites or Hispanics.African-Americans are more likely to die from diabetes than either Hispanics or whites. The overall diabetes mortality rate is 41% higher for Hispanics than for whites and 113% higher for non-Hispanic blacks than for whites.

View the original article here

Thursday, December 16, 2010

Diabetes Educators and You

Lori Bristol, RN, MSN, NCSN

She Walks Her Talk - Lori Bristol, 30 years on Insulin, Runs with Her Pump

Not Yet Rated

Sorry, I could not read the content fromt this page.

View the original article here

Diabetes may clamp down on cholesterol the brain needs

ScienceDaily (Dec. 1, 2010) ? The brain contains more cholesterol than any other organ in the body, has to produce its own cholesterol and won't function normally if it doesn't churn out enough. Defects in cholesterol metabolism have been linked with Alzheimer's disease and other neurodegenerative conditions. Now researchers at Joslin Diabetes Center have discovered that diabetes can affect how much cholesterol the brain can make.

Scientists in the laboratory of C. Ronald Kahn, M.D., head of Joslin's Integrative Physiology and Metabolism research section, found that brain cholesterol synthesis, the only source of cholesterol for the brain, drops in several mouse models of diabetes. Their work was reported online in the journal Cell Metabolism on November 30.

"Since cholesterol is required by neurons to form synapses (connections) with other cells, this decrease in cholesterol could affect how nerves function for appetite regulation, behavior, memory and even pain and motor activity," says Dr. Kahn, who is also Mary K. Iacocca Professor of Medicine at Harvard Medical School. "Thus, this has broad implications for people with diabetes." Other investigations have gathered strong evidence that people with diabetes may display varying types of alterations in brain function or ways of responding to stress, he points out.

"It is well known that insulin and diabetes play an important role in regulating cholesterol synthesis in the liver, where most of the cholesterol circulating in blood comes from," Dr. Kahn adds. "But nobody had ever suspected that insulin and diabetes would play an important role in cholesterol synthesis in the brain."

In addition to its potential role in Alzheimer's disease and other forms of neurological dysfunction, the newly discovered mechanism may play a role in diabetic neuropathy, which remains a large challenge for therapy.

People with diabetes are also known to be more prone to depression, memory loss and eating disorders than people without diabetes, and imaging studies have shown that people with diabetes have altered brain function compared to those without.

Additionally, the finding raises a question about potential interactions between anti-cholesterol drugs and diabetes.

In the Joslin study, scientists first examined gene expression in the hypothalamus of a mouse model of insulin-deficient (type 1) diabetes. They found decreased expression for almost all of the genes of cholesterol synthesis, including a gene called SREBP-2, which acts as a master regulator for cholesterol production. Similar findings were present in the cerebral cortex and other regions of the brain in these animals and also found in several other mouse models of diabetes. In the insulin-deficient animals, this phenomenon was associated with decreased cholesterol synthesis. Treatment of the mice with insulin, either by normal injection or injection into the fluid surrounding the brain, reversed the process.

"Our studies showed that these effects occurred in both the neurons and supporting 'glial' cells that help provide some nutrients to the neurons," says Kahn. "Ultimately this affects the amount of cholesterol that can get into the membranes of the neuron, which form the synapses and the synaptic vesicles -- the small structures that contain neurotransmitters."

Additionally, the Joslin work showed a connection between the decrease in brain cholesterol synthesis and appetite. When the scientists took normal mice and temporarily reduced cholesterol creation in the hypothalamus with a technique known as RNA interference, the animals started eating more and gained significant weight. Previous studies by other labs have demonstrated that diabetes may affect brain hormones involved in appetite regulation.

Ryo Suzuki, Ph.D., a postdoctoral researcher in the Kahn lab, is first author on the paper. Other Joslin contributors include Kevin Lee and Enxuan Jing. Other co-authors include Sudha B. Biddinger of Children's Hospital Boston, Jeffrey G. McDonald of the University of Texas Southwestern Medical Center, and Thomas J. Montine and Suzanne Craft of the University of Washington in Seattle. The work was supported by the National Institutes for Health, the Iacocca Foundation and the Manpei Suzuki Diabetes Foundation.

Disclaimer: This article is not intended to provide medical advice, diagnosis or treatment. Views expressed here do not necessarily reflect those of ScienceDaily or its staff.

Story Source:

The above story is reprinted (with editorial adaptations by ScienceDaily staff) from materials provided by Joslin Diabetes Center, via EurekAlert!, a service of AAAS.

Journal Reference:

Ryo Suzuki, Kevin Lee, Enxuan Jing, Sudha B. Biddinger, Jeffrey G. McDonald, Thomas J. Montine, Suzanne Craft, C. Ronald Kahn. Diabetes and Insulin in Regulation of Brain Cholesterol Metabolism. Cell Metabolism, Volume 12, Issue 6, 567-579, 1 December 2010 DOI: 10.1016/j.cmet.2010.11.006

Note: If no author is given, the source is cited instead.


View the original article here

American Diabetes Association Applauds Two-Year Re-Authorization of Special Diabetes Program

SOURCE: American Diabetes Association

ALEXANDRIA, VA--(Marketwire - December 9, 2010) - The American Diabetes Association®, the nation's leading voluntary health organization in the fight to Stop Diabetes®, praises Congress for reauthorizing the Special Diabetes Program.?The renewal, which was part of the Medicare and Medicaid Extenders Act of 2010, will ensure the Special Diabetes Program for Indians (SDPI) and the Special Diabetes Programs for Type 1 Diabetes (SDP-Type1) continue through September 2013.?The measure will provide $150 million in funding per year to each program. Nearly 24 million Americans are living with diabetes and another 57 million have prediabetes. Recently, the Centers for Disease Control and Prevention (CDC) released a report stating that if current trends continue, one in three Americans will have diabetes by the year 2050. Diabetes is among the leading causes of death by disease in the United States.?It is a leading cause of heart disease, stroke, blindness, kidney disease, and amputation.

SDPI provides prevention, education and treatment programs in Native American communities. American Indians and Alaska Natives have the highest age-adjusted prevalence of diabetes among all U.S. racial and ethnic groups, where diabetes is four to eight times more common than in the general population. Studies have demonstrated that SDPI's prevention and treatment efforts have contributed to significant reductions in diabetes complications in these targeted populations.

"We applaud the extension of the Special Diabetes Programs," said Gale Marshall, Chair, American Diabetes Association's Awakening the Spirit Native American initiative. "The Special Diabetes Program for Indians provides for more than 450 community-directed programs, allowing local tribes and health programs to set priorities that meet their needs, including prevention activities or treatment. Because of these education and treatment programs, the American Indian and Alaskan Native communities have stories of hope and progress in facing the battle against diabetes."?

The Special Diabetes Programs for Type 1 Diabetes provides funding for groundbreaking type 1 diabetes research. Clinical research supported by this program has demonstrated tangible results -- from delaying the full onset of type 1 diabetes in newly diagnosed patients to gaining insight on the underlying causes of diabetes and halting or reversing costly complications such as diabetic eye disease.

"The Special Diabetes Programs for Type 1 Diabetes is a vital federal effort that is bringing us closer to a cure for this epidemic," said Janel Wright, National Chair, Advocacy Committee, American Diabetes Association. "This cost-effective program provides crucial funding for research and results in real advances for people living with type 1 diabetes."

About The American Diabetes Association
The American Diabetes Association is leading the fight to stop diabetes and its deadly consequences and fighting for those affected by diabetes. The Association funds research to prevent, cure and manage diabetes; delivers services to hundreds of communities; provides objective and credible information; and gives voice to those denied their rights because of diabetes. Founded in 1940, our mission is to prevent and cure diabetes and to improve the lives of all people affected by diabetes. For more information please call the American Diabetes Association at 1-800-DIABETES (1-800-342-2383) or visit www.diabetes.org. Information from both these sources is available in English and Spanish.


View the original article here

Researchers Find Link Between Sugar, Diabetes And Aggression


Main Category: Diabetes
Also Included In: Psychology / Psychiatry
Article Date: 01 Dec 2010 - 3:00 PST window.fbAsyncInit = function() { FB.init({ appId: 'aa16a4bf93f23f07eb33109d5f1134d3', status: true, cookie: true, xfbml: true, channelUrl: 'http://www.medicalnewstoday.com/scripts/facebooklike.html'}); }; (function() { var e = document.createElement('script'); e.async = true; e.src = document.location.protocol + '//connect.facebook.net/en_US/all.js'; document.getElementById('fb-root').appendChild(e); }()); email icon email to a friend ? printer icon printer friendly ? write icon opinions ?
4 and a half stars1 star
A spoonful of sugar may be enough to cool a hot temper, at least for a short time, according to new research.

A study found that people who drank a glass of lemonade sweetened with sugar acted less aggressively toward a stranger a few minutes later than did people who consumed lemonade with a sugar substitute.

Researchers believe it all has to do with the glucose, a simple sugar found in the bloodstream that provides energy for the brain.

"Avoiding aggressive impulses takes self control, and self control takes a lot of energy. Glucose provides that energy in the brain," said Brad Bushman, co-author of the study and professor of communication and psychology at Ohio State University.

"Drinking sweetened lemonade helped provide the short-term energy needed to avoid lashing out at others."

The finding is more than just a medical curiosity, Bushman said. In two published papers, he and his colleagues did several studies showing that people who have trouble metabolizing, or using, glucose in their bodies show more evidence of aggression and less willingness to forgive others.

The problem is that the number of people who have trouble metabolizing glucose -- mainly those with diabetes -- is rising rapidly. From 1980 through 2008, the number of Americans with diabetes has more than tripled (from 5.6 million to 18.1 million).

"Diabetes may not only harm yourself -- it is bad for society," Bushman said. "The healthy metabolism of glucose may contribute to a more peaceful society by providing people with a higher level of energy for self-control."

Bushman conducted the lemonade study with C. Nathan DeWall and Timothy Deckman of the University of Kentucky and Matthew Gailllot of SUNY-Albany. It appears online in the journal Aggressive Behavior and will be published in a future print edition.

In the study, 62 college students fasted for three hours to reduce glucose instability. They were told they were going to participate in a taste-test study, and then have their reaction times evaluated in a computerized test against an opponent.

Half of the participants were given lemonade sweetened with sugar, while the others were given lemonade with a sugar substitute.

After waiting eight minutes to allow the glucose to be absorbed in their bloodstream, the participants took part in the reaction test.

The reaction test has been used and verified in other studies as a way to measure aggression. Participants were told they and an unseen partner would press a button as fast as possible in 25 trials, and whoever was slower would receive a blast of white noise through their headphones.

At the beginning of each trial, participants set the level of noise their partner would receive if they were slower. The noise was rated on a scale of 1 to 10 -- from 60 decibels to 105 decibels (about the same volume as a smoke alarm).

In actuality, each participant won 12 of the 25 trials (randomly determined).

Aggression was measured by the noise intensity participants chose on the first trial -- before they were provoked by their partner.

Results showed that participants who drank the lemonade sweetened with sugar behaved less aggressively than those who drank lemonade with a sugar substitute. Those who drank the sugar-sweetened beverage chose a noise level averaging 4.8 out of 10, while those with the sugar substitute averaged 6.06.

"To our knowledge, this is the first study to find that boosting glucose levels can reduce actual aggressive behavior," Bushman said.

"To be sure, consuming sugar should not be considered a panacea for curbing aggression. But the results do suggest that people who reportedly "snap" with aggression may need some way to boost their mental energy, so they can override their aggressive impulses."

In two other studies in the same paper, the researchers showed how problems metabolizing glucose may translate to problems on a societal level. Using 2001 data, the researchers found that the diabetes rates for each of the 50 states were linked to violent crime rates. Those states with higher diabetes rates also tended to have higher rates of murder, assault, rape and robbery, even after controlling for poverty rates in each state.

"This suggests that diabetes did not predict violent crime simply because poverty contributes to both diabetes and violent crime," he said. "There is a real correlation between diabetes and violence."

In a separate analysis, the researchers tested whether another medical problem related to glucose metabolism was linked to violence worldwide.

They examined the prevalence, in the populations of 122 countries around the world, of a deficiency in an enzyme called glucose-6-phosphate dehydrogenase. This enzyme is related to glucose metabolism. It is the most common enzyme deficiency in the world, afflicting more than 400 million people.

Countries with higher levels of the disorder also had more violent killings, even outside of war.

"Taken together, these studies offer different types of evidence linking low glucose and other problems metabolizing glucose with aggression and violence," Bushman said.

The findings were further corroborated in another series of studies, published recently in the journal Personality and Individual Differences.

In that paper, Bushman and DeWall, along with University of Kentucky researcher Richard Pond, had participants complete a commonly used and well-accepted checklist that measures the number and severity of Type 2 diabetes symptoms, such as numbness in the feet, shortness of breath at night, and overall sense of fatigue. In three separate studies, the same participants completed different measures of their willingness to forgive others.

On all three measures, people with higher levels of diabetic symptoms were less likely to forgive others for their transgressions.

In a fourth study, participants took part in a prisoner's dilemma game, which is often used to understand how people deal with conflict. In this version, participants had to choose whether to cooperate or compete against an unseen partner in a computer game.

"We were especially interested in how participants responded when their partner behaved in an uncooperative, antagonizing manner when the game began," Bushman said. "Would they forgive their partner or would they refuse to cooperate?"

Results showed that those who scored higher on diabetic symptoms were less likely to forgive an initially uncooperative partner, when compared to those who scored lower on diabetic symptoms.

"These studies are more evidence that diabetic symptoms may cause difficulty in how people relate to each other on a day-to-day basis," Bushman said.

"It's not an excuse diabetes does not mean people have to act aggressively, but it may shed some light on why these behaviors occur."

"With the rate of diabetes increasing worldwide, it is something that should concern all of us."

Source: Ohio State University

Please rate this article:
(Hover over the stars
then click to rate) Bookmark and Share

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.

All opinions are moderated before being added.

Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:






View the original article here

Diabetes spike in Queensland

Far north Queensland is in the grip of a diabetes spike with some local government areas having up to 60 per cent of the population affected.

While some indigenous communities have recorded extraordinarily high levels of diabetes, the region as a whole has showed a marked increase in the incidence of the disease, as has the general Queensland population.

Two million Queenslanders were at risk, Diabetes Australia said.

In the Cairns local government area, 4.5 per cent of population have diabetes, up from 3.3 per cent in 2007.

In the Mt Isa local government area, 4.8 per cent of population has diabetes, up from 3.4 per cent in 2007.

In indigenous communities, Mapoon has 60 per cent of its population with diabetes - up from 23 per cent in 2007, Wujal Wujal has 44.7 per cent, and Hope Vale 28.5 per cent, with others having smaller levels but showing a marked increase since 2007.

The figures from the Queensland branch of Diabetes Australia reveal that 66 of Queensland's 74 local government areas are hotspots for diabetes, a dramatic increase on 2007 figures.

CEO Michelle Trute said the 2010 data showed 27 local government areas had a diabetes incidence above seven per cent of the population, compared with only 16 areas having such high levels in 2007.

'Diabetes is the fastest growing non-infectious disease in the world and two million Queenslanders are at risk of type 2 diabetes because they are overweight,' Ms Trute said.

'Despite campaigns such as our National Diabetes Week and Queensland Government programs Eat Well Be Active and Smart Choices, it is clear from this new data that more needs to be done.'

Diabetes-related medical cases now occupied one-in-five Queensland hospital beds, and diabetes was the number one cause of avoidable hospitalisations in the state, Ms Trute said.


View the original article here

Diabetes Affects Brain Cholesterol

Posted on: Tuesday, 30 November 2010, 14:23 CST

Researchers at Joslin Diabetes Center have discovered that diabetes is able to affect how much cholesterol the brain is able to produce.

Scientists have discovered that brain cholesterol synthesis, which is the only source of cholesterol for the brain, dropped in several mouse models of diabetes.?

"Since cholesterol is required by neurons to form synapses (connections) with other cells, this decrease in cholesterol could affect how nerves function for appetite regulation, behavior, memory and even pain and motor activity," says Dr. Kahn, who is also Mary K. Iacocca Professor of Medicine at Harvard Medical School.? "Thus, this has broad implications for people with diabetes."

Kahn wrote in the journal Cell Metabolism that other research has found that people with diabetes may display varying types of alterations in brain function or ways of responding to stress.

"It is well known that insulin and diabetes play an important role in regulating cholesterol synthesis in the liver, where most of the cholesterol circulating in blood comes from," Kahn adds. "But nobody had ever suspected that insulin and diabetes would play an important role in cholesterol synthesis in the brain."

If the brain does not produce enough cholesterol, then it can lead to Alzheimer's disease and other neurodegenerative conditions.

The newly discovered mechanism may help play a role in diabetic neuropathy, which still remains a large challenge for therapy.

People with diabetes are also known to suffer from depression, memory loss and eating disorders.?

The researchers examined gene expression in the hypothalamus of a mouse with type-1 diabetes.? They found decreased expression for almost all of the genes of cholesterol synthesis, including a gene called SREBP-2, which acts as a master regulator for cholesterol production.?

The team also discovered that similar findings were present in the cerebral cortex and other regions of the brain in these animals.?

This phenomenon was associated with decreased cholesterol synthesis.? Treating the mice with insulin helps to reverse the process.

"Our studies showed that these effects occurred in both the neurons and supporting 'glial' cells that help provide some nutrients to the neurons," Kahn wrote. "Ultimately this affects the amount of cholesterol that can get into the membranes of the neuron, which form the synapses and the synaptic vesicles?the small structures that contain neurotransmitters."

He said that the results raise the prospect that cholesterol-lowering statins might have unintended consequences for the brain and its function.? The researchers said that earlier studies designed to look for a potential effect of statins on cognitive function in patients have yielded conflicting results.

---

On the Net:

Source: RedOrbit Staff & Wire Reports

More News in this Category


View the original article here

Type 1 diabetes computer model's predictive success validated through lab testing

ScienceDaily (Dec. 9, 2010) ? A La Jolla Institute team, led by leading type 1 diabetes researcher Matthias von Herrath, M.D., has demonstrated the effectiveness of a recently developed computer model in predicting key information about nasal insulin treatment regimens in type 1 (juvenile) diabetes.

The findings, which also showed the platform's ability to predict critical type 1 diabetes molecular "biomarkers," were published in the December issue of the scientific journal Diabetes, and further validate the importance of the new model as a valuable research tool in type 1 diabetes. The software is designed to enable researchers to rapidly streamline laboratory research through the evaluation of alternative scenarios for therapeutic strategies that show the most promise for working in humans.

"Since laboratory studies can cost hundreds of thousands of dollars, and early stage human clinical trials can cost $10 million dollars or more, predicting the right conditions to try is important," said Dr. von Herrath, director of the Type 1 Diabetes Research Center at the La Jolla Institute for Allergy & Immunology, where the studies were conducted.

Development of the software, the Type 1 Diabetes PhysioLab® Platform, was funded through the peer-reviewed grant program of the American Diabetes Association.

"We've found that using this in silico (computer analysis) prediction platform can quicken the pace and effectiveness of type 1 diabetes research," he continued. "By allowing us to pre-test our theories in computer models, we can ensure that the more time-intensive and costly process of laboratory testing is focused on the most promising therapeutic strategies, with the greatest chance of success."

The platform, developed by Entelos Inc., a life sciences company specializing in predictive technologies, has previously been shown to successfully predict various data from published type 1 diabetes experiments. Dr. von Herrath's team used a different approach to test the model, asking it to predict the outcome of a hypothetical experiment on nasal insulin dosing frequency in animal models that had not yet been performed. The prediction was then tested in the laboratory, where its results were confirmed.

In addition, he said, the model was able to accurately identify the particular time frame at which key type 1 diabetes "biomarkers" kicked in. Biomarkers are specific cell types or proteins that tell researchers at what point a therapeutic option is working or when it is time to start treatment. In the case of the La Jolla Institute study, the model successfully predicted the onset of biomarkers indicating beta cell protection in the NOD mouse.

"The model accurately predicted that implementing a low frequency nasal insulin dosing regimen in animal models was more beneficial in controlling type 1 diabetes than a high frequency regimen," said Dr. von Herrath, noting that the software's prediction of the biomarkers was key in this process. "These results confirmed our hypotheses on the benefits of low-frequency nasal insulin dosing. But even more importantly, the advantage of applying computer modeling in optimizing the therapeutic efficacy of nasal insulin immunotherapy was confirmed."

The results were reported in the paper "Virtual Optimization of Nasal Insulin Therapy Predicts Immunization Frequency To Be Crucial for Diabetes Protection." Dr. von Herrath was senior author on the paper and La Jolla Institute scientist Georgia Fousteri, Ph.D., and Jason Chan, Ph.D., from Entelos' R&D group, were first co-authors.

The Type 1 Diabetes PhysioLab® Platform is a large-scale mathematical model of disease pathogenesis based on non-obese diabetic (NOD) mice. The platform was developed with input from an independent scientific team of leading type 1 diabetes experts. The research support group of the American Diabetes Association funded the work of the software's development to provide a new scientific tool for enhancing the speed and effectiveness of type 1 diabetes research.

More than 400,000 children worldwide suffer from type 1 diabetes, a chronic disease that can lead to severe complications, such as blindness, cardiovascular disease, renal disease, coma or even death.

The platform, developed over two years, simulates autoimmune processes and subsequent destruction of pancreatic beta cells from birth through frank diabetes onset (hyperglycemia). The destruction of insulin-producing beta cells in the pancreas is the underlying cause of type 1 diabetes.

Specifically, Dr. von Herrath's team employed the model to investigate the possible mechanisms underlying the effectiveness of nasal insulin therapy, using the B: 9-23 peptide. "The experimental aim was to evaluate the impact of dose, frequency of administration and age at treatment on key molecular mechanisms and optimal therapeutic outcome," he said.

Using parameters input by the scientific team, the model accurately predicted that less frequent doses of nasal insulin, started at an early disease stage, would protect more effectively against beta cell destruction than higher frequency doses in NOD mice.

Dr. von Herrath added that the positive results add credence to the idea of creating computer models for analyzing therapeutic interventions in human disease. "These results support the development and application of humanized platforms for the design of clinical trials," he said.

Disclaimer: This article is not intended to provide medical advice, diagnosis or treatment. Views expressed here do not necessarily reflect those of ScienceDaily or its staff.

Story Source:

The above story is reprinted (with editorial adaptations by ScienceDaily staff) from materials provided by La Jolla Institute for Allergy and Immunology, via EurekAlert!, a service of AAAS.

Journal Reference:

G. Fousteri, J. R. Chan, Y. Zheng, C. Whiting, A. Dave, D. Bresson, M. Croft, M. von Herrath. Virtual Optimization of Nasal Insulin Therapy Predicts Immunization Frequency to Be Crucial for Diabetes Protection. Diabetes, 2010; 59 (12): 3148 DOI: 10.2337/db10-0561

Note: If no author is given, the source is cited instead.


View the original article here

Wednesday, December 15, 2010

Smoking widespread among youth with diabetes, raising heart disease risk

ScienceDaily (Dec. 3, 2010) ? Cigarette smoking is widespread among children and young adults with diabetes yet few health care providers are counseling children and young adults with diabetes to not smoke or stop smoking, according to a new report from the SEARCH Study Group, published online in the Journal of Pediatrics.

Children and young adults with diabetes are already at high risk for heart disease before they take up smoking but few studies have examined the association between cigarette smoking and heart disease risk factors in youth with diabetes.

Funded by the Centers for Disease Control and Prevention and the National Institute of Diabetes and Digestive Kidney Diseases, the study examined tobacco use and heart disease risk factors in a racially and ethnically diverse group of 3,466 children and young adults with diabetes aged 10 to 22 years old across the United States.

Researchers found that 10 percent of youth with type 1 diabetes and 16 percent of youth with type 2 diabetes were currently using some form of tobacco products: cigarettes, cigars or smokeless tobacco. Less than half of the youth reported that they had been counseled by their health care provider to not smoke or stop smoking.

"We found a substantial proportion of youth with diabetes are current cigarette smokers, which greatly adds to their already elevated risk for heart disease," said study lead author Kristi Reynolds, PhD, MPH, a research scientist and epidemiologist at the Kaiser Permanente Southern California Department of Research & Evaluation. "Smoking is preventable, so aggressive smoking prevention and cessation programs are needed to prevent or delay heart disease in youth with diabetes."

These findings were based on analysis of data from the SEARCH for Diabetes in Youth Study, a large multi-center study of youth diagnosed with diabetes before the age of 20 years who were enrolled by six clinical centers in California, Colorado, Hawaii, Ohio, South Carolina and Washington.

The study found the prevalence of current cigarette smoking in youth with type 1 diabetes to be 1.3 percent of 10- to 14-year-olds, 14.9 percent of 15- to 19-year-olds, and 27 percent of those 20 years and older. Among youth with type 2 diabetes, 4.4 percent of 10- to 14-year-olds were currently cigarette smokers, 12.9 percent of 15- to 19-year-olds were cigarette smokers, and 37.3 percent in youth 20 years and older were cigarette smokers.

The study also found early signs of heart disease among those using cigarette products. Youth who were past and current smokers had a higher prevalence of high triglyceride levels, high LDL cholesterol levels, low HDL cholesterol levels and more physical inactivity than non-smokers.

"Cigarette smoking is a completely preventable risk factor for cardiovascular and other diseases. While this is true for all children, it is especially true for children with diabetes because of the increased risk of cardiovascular disease in that population," said study co-author Stephen R. Daniels, MD, PhD, professor and chairman of the Department of Pediatrics at the University of Colorado School of Medicine and Pediatrician-in-Chief at The Children's Hospital in Denver.

In adults with diabetes, the risk of heart disease is greatly increased compared with adults without diabetes, and smoking may increase that risk. About 90 percent of adult smokers started smoking before age 18. Because of the already increased risk of cardiovascular disease in individuals with diabetes mellitus, the American Diabetes Association emphasizes the importance of smoking cessation for those individuals.

Other study authors included: Jean M. Lawrence, ScD, MPH, MSSA, from the Kaiser Permanente Southern California Department of Research & Evaluation in Pasadena, Calif; Angela D. Liese, PhD, MPH, from the Center for Research in Nutrition and Health Disparities and Department of Epidemiology and Biostatistics, University of South Carolina, Columbia, S.C.; Andrea M. Anderson, MS, and Doug Case, PhD, from the Department of Biostatistical Sciences, Wake Forest University School of Medicine, Winston-Salem, N.C.; Dana Dabelea, MD, PhD, from the Department of Epidemiology, Colorado School of Public Health, University of Colorado at Denver; Debra Standiford, MSN, CNP, from the Division of Endocrinology, Cincinnati Children's Hospital, Cincinnati; Stephen R. Daniels, MD, PhD, from Department of Pediatrics, University of Colorado Denver School of Medicine, Aurora, Colo.; Beth Waitzfelder, PhD, from the Pacific Health Research Institute in Honolulu; Beth Loots, MPH, MSW, from Seattle Children's, Seattle,; and Giuseppina Imperatore, MD, PhD, from the Division of Diabetes Translation, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Atlanta.

Disclaimer: This article is not intended to provide medical advice, diagnosis or treatment. Views expressed here do not necessarily reflect those of ScienceDaily or its staff.

Story Source:

The above story is reprinted (with editorial adaptations by ScienceDaily staff) from materials provided by Kaiser Permanente, via EurekAlert!, a service of AAAS.

Journal Reference:

Kristi Reynolds, Angela D. Liese, Andrea M. Anderson, Dana Dabelea, Debra Standiford, Stephen R. Daniels, Beth Waitzfelder, Doug Case, Beth Loots, Giuseppina Imperatore. Prevalence of Tobacco Use and Association between Cardiometabolic Risk Factors and Cigarette Smoking in Youth with Type 1 or Type 2 Diabetes Mellitus. The Journal of Pediatrics, 2010; DOI: 10.1016/j.jpeds.2010.10.011

Note: If no author is given, the source is cited instead.


View the original article here

Low vitamin-D levels found in northern California residents with metabolic syndrome

ScienceDaily (Nov. 30, 2010) ? Researchers from the UC Davis Health System have found that compared with healthy controls, blood levels of vitamin D are significantly reduced in patients in the Sacramento area with metabolic syndrome, a constellation of disease risk factors that affects about one in three U.S. adults and predisposes them to diabetes, heart disease and stroke.

The study is the first to examine vitamin-D status in patients with metabolic syndrome living in Northern California, where the many hours of sunshine make the vitamin-D deficiency finding surprising. The study was published online November 30 and will appear in the January 2011 issue of the journal Hormone and Metabolic Research.

"In spite of our great sun exposure in Northern California, 30 percent of patients with metabolic syndrome have vitamin-D deficiency, and even many subjects in the control group had inadequate levels," said Ishwarlal Jialal, the study's principal investigator and professor of pathology and laboratory medicine at the UC Davis Health System. "Considering our climate and healthy lifestyles here, these findings were unexpected."

The study measured serum vitamin D levels in 44 people with metabolic syndrome and compared them to 37 healthy controls matched for age and gender. They found that 30 percent of subjects with metabolic syndrome were deficient in vitamin D compared with eight percent of controls. The difference between the groups was statistically significant and could not be explained by differences in sun exposure or other factors that are known to alter vitamin-D levels, such as kidney disease and amount of body fat. Furthermore, the low levels correlated with risk of diabetes such as insulin resistance and plasma glucose levels.

Metabolic syndrome has become highly prevalent in the United States with the obesity epidemic. The syndrome is characterized by having at least three of the following risk factors: a large waistline, a high blood-triglyceride level, a low-blood level of high-density lipoprotein (HDL) cholesterol, high-blood pressure and high-fasting blood sugar. These factors indicate disturbances in the body's metabolism, conferring at least a five-fold increased risk of developing diabetes and doubling the risk for developing cardiovascular diseases, including heart attack and stroke.

Vitamin D is a nutrient that has come under increased scrutiny in recent years as more of its roles in the human body are discovered. It has long been known to be important for healthy bone growth and maintaining normal calcium levels in the blood. More recent studies have also linked low vitamin-D levels to an increased risk of diabetes and cardiovascular disease as well as many cancers. Reduced vitamin D levels are also associated with higher fasting blood sugar, more insulin resistance and increased body fat, components of the metabolic syndrome.

Vitamin D is obtained naturally through sun exposure as well as through certain foods, including fish, liver and eggs. It can also be taken through supplements, and many dairy products, margarines and cereals are fortified with it. Although most people in California are traditionally thought to receive adequate vitamin D through routine outdoor activity, this study indicates that this is not the case in Northern California. A similar study recently conducted in Southern California found no difference in vitamin-D levels between subjects with and without metabolic syndrome, and in Florida, even diabetics do not tend to have low vitamin-D levels. These results indicate that vitamin D levels are probably adequate for most people living in those sunny latitudes, and that metabolic syndrome and diabetes arise mostly because of other factors in those areas.

"That our results were so different from the study undertaken in Southern California was amazing to us," said Jialal, who also serves as director of the Laboratory for Atherosclerosis and Metabolic Research at UC Davis. "The difference in latitude is not that great, but apparently sun exposure in southern California is adequate and in northern California it is not."

Controversy exists surrounding optimum blood levels of vitamin D. Current government guidelines for sufficient blood levels of vitamin D as well as daily intake are based on those required for bone health and are much lower than what are now believed by many experts to help prevent cancer, diabetes and cardiovascular disease. National Institutes of Health guidelines recommend a minimum blood level of 15 ng/mL as adequate for bone and overall health. However, many experts now feel that 30 to 100 ng/mL should be the goal. Levels above 150 ng/mL are potentially toxic and can be life-threatening.

In this study, vitamin D levels averaged 23.1 ng/mL among people with metabolic syndrome and 27.8 ng/mL in healthy controls, a difference that was found to be significant. Vitamin D deficiency in this study was defined as less than 20 ng/mL, and was found in 30 percent of subjects with metabolic syndrome and 8 percent of healthy controls. "Insufficiency" was defined as less than 30 ng/mL: 84 percent of the metabolic syndrome group and 67 percent of controls were found to have insufficient levels.

Jialal's team intends to continue to investigate the connections between vitamin D and metabolic syndrome. They plan to study diets of subjects with and without metabolic syndrome to determine whether vitamin D intake is adequate. According to Jialal, it is possible that people with metabolic syndrome have higher than average needs for vitamin D. Because the vitamin is fat-soluble, it tends to get sequestered in fat, making it less likely to circulate in the blood and to be available to other tissues.

They also plan to undertake a study on vitamin D supplementation for people with metabolic syndrome to see if it lowers fasting blood sugars and increases insulin sensitivity, trends that would lower the risk of developing diabetes.

"We have the potential to significantly delay or prevent the emergence of diabetes, heart attacks and strokes in people with metabolic syndrome through vitamin D supplementation," said Dr. Jialal. "This may offer a very simple yet powerful weapon to combat this burgeoning health problem in our society."

The other UC Davis study authors include Professor Sridevi Devaraj, student volunteer Ganesh Jialal and technologist Teri Cook measured the vitamin-D levels. David Siegel assisted in the study design and manuscript preparation. This study was supported by grants from the National Institutes of Health and American Diabetes Association.

Disclaimer: This article is not intended to provide medical advice, diagnosis or treatment. Views expressed here do not necessarily reflect those of ScienceDaily or its staff.

Story Source:

The above story is reprinted (with editorial adaptations by ScienceDaily staff) from materials provided by University of California - Davis Health System, via EurekAlert!, a service of AAAS.

Journal Reference:

Ishwarlal Jialal et al. Low vitamin D levels in North American adults with the metabolic syndrome. Hormone and Metabolic Research, November 30, 2010

Note: If no author is given, the source is cited instead.


View the original article here

Molecular 'switch' contributes to cellular aging process: Discovery suggests new treatments for metabolic diseases

ScienceDaily (Nov. 30, 2010) ? A team of Harvard School of Public Health (HSPH) scientists reports finding a molecular "switch" that can "turn off" some cellular processes that are protective against aging and metabolic diseases. While more research is needed, the findings may open doors for new drug treatments to halt or slow development of metabolic diseases like type 2 diabetes or heart disease. The research findings appear in the December 1, 2010 issue of Cell Metabolism.

Scientists want to better understand why some people -- often those who are older, overweight, or obese -- develop metabolic syndrome, a condition characterized by a group of risk factors, including high blood glucose, high cholesterol, insulin resistance, fatty liver, and increased abdominal fat. This condition increases the risk of heart disease, type 2 diabetes, and other diseases, including cancer.

Using genetically altered mouse models, senior author Chih-Hao Lee, assistant professor of genetics and complex diseases at HSPH, first author Shannon Reilly, an HSPH graduate student, and their colleagues focused on the role of the protein SMRT (silencing mediator of retinoid and thyroid hormone receptors) in the aging process. They found aged cells accumulate more SMRT and wanted to see if SMRT increases the damaging effects of oxidative stress on mitochondria, the cell component that converts food and oxygen into energy and powers metabolic activities. Oxidative stress is a cellular process that damages DNA, protein, and other cell functions and can lead to age-related diseases such as type 2 diabetes, Alzheimer's, Parkinson's, and atherosclerosis.

In laboratory experiments, Reilly, Lee, and colleagues found that in older animals SMRT acts like a "switch," turning off the protective cellular activities of proteins known as peroxisome proliferator-activated receptors (PPARs). PPARs help regulate genes that promote fat burning to maintain lipid (blood fat) balance and reduce oxidative stress. The researchers were able to reduce the negative effects of oxidative stress by giving antioxidants or drugs known to turn the protective activities of PPARs back on.

The scientists knew that oxidative damage causes the body to age. What they did not know is why aged cells have more oxidative damage. "The significance of our study is that we show SMRT facilitates this process," Lee said. "In other words, the normal metabolic homeostasis is maintained, in part, by PPARs. SMRT acts as a metabolic switch to turn off PPAR activities when the cells age."

PPAR drugs have been used to increase insulin sensitivity and lower blood lipid levels. "Our study shows PPARs might also be used to boost the body's ability to handle oxidative stress," Lee said.

"With what we have learned, we believe SMRT is one of the key players that causes age-dependent decline in mitochondrial function by blocking PPAR activity, and we've found a way to boost the body's ability to better handle metabolic and oxidative stress," Lee said. "This finding is significant since increased oxidative stress, coupled with reduced metabolic function, contributes to the aging process and the development of age-related metabolic diseases."

In collaboration with epidemiologists at HSPH, the team found genetic variations in the human SMRT gene that are associated with risk of type 2 diabetes. "Through this study we were able to validate that our findings in the animal model apply to human diseases," Lee said.

Support for the study was from the National Institutes of Health as well as from the American Diabetes Association and American Heart Association. Lee received a Career Incubator Fund from HSPH that also supported the work.

Disclaimer: This article is not intended to provide medical advice, diagnosis or treatment. Views expressed here do not necessarily reflect those of ScienceDaily or its staff.

Story Source:

The above story is reprinted (with editorial adaptations by ScienceDaily staff) from materials provided by Harvard School of Public Health, via EurekAlert!, a service of AAAS.

Journal Reference:

Shannon M. Reilly, Prerna Bhargava, Sihao Liu, Matthew R. Gangl, Cem Gorgun, Russell R. Nofsinger, Ronald M. Evans, Lu Qi, Frank Hu, Chih-Hao Lee. Nuclear Receptor Corepressor SMRT Regulates Mitochondrial Oxidative Metabolism and Mediates Aging-Related Metabolic Deterioration. Cell Metabolism, 2010; DOI: 10.1016/j.cmet.2010.11.007

Note: If no author is given, the source is cited instead.


View the original article here

Diabetes spike in north Queensland

AAP

Far north Queensland is experiencing a dramatic increase in the rate of diabetes with some local government areas having up to 60 per cent of the population affected.

While some indigenous communities have recorded extraordinarily high levels of diabetes, the region as a whole has showed a marked increase in the incidence of the disease, as has the general Queensland population.

Two million Queenslanders were at risk, Diabetes Australia said.

Advertisement: Story continues below

In the Cairns local government area, 4.5 per cent of population have diabetes, up from 3.3 per cent in 2007.

In the Mt Isa local government area, 4.8 per cent of population has diabetes, up from 3.4 per cent in 2007.

In indigenous communities, Mapoon has 60 per cent of its population with diabetes - up from 23 per cent in 2007, Wujal Wujal has 44.7 per cent, and Hope Vale 28.5 per cent, with others having smaller levels but showing a marked increase since 2007.

The figures from the Queensland branch of Diabetes Australia reveal that 66 of Queensland's 74 local government areas are hotspots for diabetes, a dramatic increase on 2007 figures.

CEO Michelle Trute said the 2010 data showed 27 local government areas had a diabetes incidence above seven per cent of the population, compared with only 16 areas having such high levels in 2007.

"Diabetes is the fastest growing non-infectious disease in the world and two million Queenslanders are at risk of type 2 diabetes because they are overweight," Ms Trute said.

"Despite campaigns such as our National Diabetes Week and Queensland Government programs Eat Well Be Active and Smart Choices, it is clear from this new data that more needs to be done."

Diabetes-related medical cases now occupied one-in-five Queensland hospital beds, and diabetes was the number one cause of avoidable hospitalisations in the state, Ms Trute said.


View the original article here

Albert Einstein College Of Medicine To Study Impact Of Resveratrol On Prediabetes


Main Category: Diabetes
Also Included In: Endocrinology;??Nutrition / Diet;??Clinical Trials / Drug Trials
Article Date: 09 Dec 2010 - 4:00 PST window.fbAsyncInit = function() { FB.init({ appId: 'aa16a4bf93f23f07eb33109d5f1134d3', status: true, cookie: true, xfbml: true, channelUrl: 'http://www.medicalnewstoday.com/scripts/facebooklike.html'}); }; (function() { var e = document.createElement('script'); e.async = true; e.src = document.location.protocol + '//connect.facebook.net/en_US/all.js'; document.getElementById('fb-root').appendChild(e); }()); email icon email to a friend ? printer icon printer friendly ? write icon opinions ?
4 starsnot yet rated
Researchers at Albert Einstein College of Medicine of Yeshiva University have been awarded $600,000 from the American Diabetes Association (ADA) to study the effect of resveratrol, a chemical compound most notably found in red wine and grapes, on impaired glucose tolerance (IGT) in older adults. IGT occurs when blood glucose levels are higher than normal, but not high enough to be considered diabetes. The condition is also known as prediabetes.

IGT and diabetes increase dramatically with age, affecting almost 40 percent of adults over age 60. According to the ADA, those with prediabetes have a 50 percent increased risk of heart attack and stroke. Results of this study will provide critical information that is needed to plan and conduct more definitive studies of resveratrol in the prevention and treatment of type 2 diabetes.

"Our earlier work in the area has given us reason to be hopeful," said Jill Crandall, M.D., professor of clinical medicine and director of the Diabetes Clinical Trials Unit. "Given the easy availability, low cost and apparent safety of resveratrol supplementation, a positive finding could have an enormous impact on human health."

The ADA grant will fund a six-week double-blind, placebo-controlled cross-over study of thirty individuals between the ages of 50 and 80 years of age who have IGT. Study participants will be given resveratrol supplements to explore the compound's effects on post-meal blood glucose metabolism. Preliminary studies will also be conducted to explore how resveratrol works by examining cellular function (in muscle samples obtained from study participants) and testing resveratrol's effect on blood vessel function.

Resveratrol supplements are needed because diet alone is not sufficient to supply what is believed to be a therapeutic concentration of the compound. It's estimated that a person would need to drink between 100-1000 bottles of wine per day to receive the levels shown to be therapeutic in mice.

In research in cells and animals, resveratrol has been shown to prolong lifespan, prevent cancer and heart disease, and normalize glucose metabolism. Although use of this agent shows great promise in the treatment and/or prevention of diabetes, there have been no rigorously controlled, peer-reviewed clinical studies in humans.

Source: Albert Einstein College of Medicine of Yeshiva University

Please rate this article:
(Hover over the stars
then click to rate) Bookmark and Share

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.

All opinions are moderated before being added.

Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:






View the original article here

Alzheimer's Patients Could Benefit From Diabetes Drug


Main Category: Alzheimer's / Dementia
Also Included In: Diabetes
Article Date: 26 Nov 2010 - 3:00 PST window.fbAsyncInit = function() { FB.init({ appId: 'aa16a4bf93f23f07eb33109d5f1134d3', status: true, cookie: true, xfbml: true, channelUrl: 'http://www.medicalnewstoday.com/scripts/facebooklike.html'}); }; (function() { var e = document.createElement('script'); e.async = true; e.src = document.location.protocol + '//connect.facebook.net/en_US/all.js'; document.getElementById('fb-root').appendChild(e); }()); email icon email to a friend ? printer icon printer friendly ? write icon opinions ?
4 and a half stars5 stars
Metformin, a drug used in type 2-diabetes might have the potential to also act against Alzheimer's disease. This has been shown in a study from scientists of the German Center for Neurodegenerative Diseases (DZNE), the University of Dundee and the Max-Planck-Institute for Molecular Genetics. The researchers have found out that the diabetes drug metformin counteracts alterations of the cell structure protein Tau in mice nerve cells. These alterations are a main cause of the Alzheimer's disease. Moreover, they uncovered the molecular mechanism of metformin in this process. "If we can confirm that metformin shows also an effect in humans, it is certainly a good candidate for an effective therapy on Alzheimer's diseases," says Sybille Krauß from DZNE. Their results have been published in the scientific journal PNAS.

Alzheimer's disease is a form of dementia that affects almost exclusively elderly people. Today, about 700,000 people are suffering from Alzheimer's disease in Germany. Neurons in their brains die, leading to cognitive impairment. At the molecular level, the disease is characterized amongst others by the formation of Tau protein deposits in nerve cells. Tau is a molecule that usually binds to the supportive cytoskeleton and performs a function in the transport system of the cell. In Alzheimer's disease, Tau is tipped too strongly with phosphate groups. This phosphorylation causes removal of Tau from the cytoskeleton and aggregation.

To counteract this problem, researchers aimed at regulating the protein PP2A. This protein is normally responsible for removing phosphate groups from Tau protein. In Alzheimer's disease, PP2A is not active enough - leading to an increased phosphorylation and deposition of Tau. The scientists around Sybille Krauß and Susann Schweiger (University of Dundee) therefore looked for a drug that increases the activity of PP2A. "So far there is no drug on the market that targets the formation of tau aggregates," says Krauß.

In cell culture experiments with mouse nerve cells, the researchers showed that metformin directly protects PP2A against degradation by preventing the binding to special degradation proteins. This mechanism of metformin has been unknown so far. In addition, an increase in PP2A activity leads to a reduction in Tau phosphorylation. In a next step, the scientists added metformin to drinking water of healthy mice. This also led to a reduction of Tau-phoshorylation in brain cells. In further experiments, the researchers now intend to investigate, whether metformin prevents the deposition of tau proteins also in mouse models of Alzheimer's disease and improves cognitive performance of the animals. The effect in humans will then be tested in clinical studies. There is no risk of unexpected side effects, due to the fact that the drug is already used against diabetes.

Original paper:
Kickstein E, Krauss S, Thornhill P, Rutschow D, Zeller R, Sharkey J, Williamson R, Fuchs M, Kohler A, Glossmann H, Schneider R, Sutherland C, Schweiger S: The Biguanide metformin acts on tau phosphorylation via mTOR/PP2A signalling. PNAS published ahead of print November 22, 2010, doi:10.1073/pnas.0912793107.

Source:
Dr. Katrin Weigmann
Helmholtz Association of German Research Centres

Please rate this article:
(Hover over the stars
then click to rate) Bookmark and Share

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.

All opinions are moderated before being added.

Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:






View the original article here

Tuesday, December 14, 2010

Sixth Global Conference On Stem Cell Therapy To Be Held Jan. 20-21, 2011, In New York City


Main Category: Conferences
Also Included In: Heart Disease;??Stem Cell Research;??Diabetes
Article Date: 03 Dec 2010 - 1:00 PST window.fbAsyncInit = function() { FB.init({ appId: 'aa16a4bf93f23f07eb33109d5f1134d3', status: true, cookie: true, xfbml: true, channelUrl: 'http://www.medicalnewstoday.com/scripts/facebooklike.html'}); }; (function() { var e = document.createElement('script'); e.async = true; e.src = document.location.protocol + '//connect.facebook.net/en_US/all.js'; document.getElementById('fb-root').appendChild(e); }()); email icon email to a friend ? printer icon printer friendly ? write icon opinions ?
not yet ratednot yet rated
WHAT:
The Sixth International Conference on Cell Therapy for Cardiovascular Disease (IC3D) is a one-and-a-half day comprehensive program dedicated to the evolving field of cell-based therapies for the repair and regeneration of cardiac and vascular disease, as well as related diseases such as diabetes and stroke. This year's conference will focus on commercialization aspects of the field, highlighting the status of molecular, cell, and tissue products in addition to delivery systems.

WHY:
Now in its 10th year of clinical trials, the application of stem cells in the treatment of cardiovascular diseases has seen many notable successes, as well as identified challenges that await the next round of clinical studies. Leaders in the field will convene to present their work, experiences, observations, and opinions on the benefits and unmet challenges of cell-based therapies.

Sessions will focus on: Autologous cell products Allogenic cells, hybrid preparations, and specialty products Molecular interventions: Macro and micro agents Delivery methods and imaging Selection of biologics and methodologies in the development of the next generation of clinical trials WHO:
Warren Sherman, MD, Course Director, is Director of Cardiac Cell-Based Endovascular Therapies at the Center for Interventional Vascular Therapy at NewYork-Presbyterian Hospital and Columbia University Medical Center. Dr. Sherman is a renowned clinical investigator in the field of myocardial regeneration who pioneered a technique for injecting stem cells into the heart. In Rotterdam in May 2001, he performed the first catheter-based injection of stem cells into the heart of a patient with congestive heart failure due to a previous heart attack. At Columbia University Medical Center, researchers led by Dr. Sherman are using the patient's own myoblasts -- progenitor cells found in muscle -- to repair and replace injured cardiac tissue in a process called myogenesis. Dr. Sherman collaborates in studies to improve the outcomes of cell implantation with colleagues at Columbia University Medical Center, all of whom will be presenting their research at the conference.

WHEN:
January 20-21, 2011

WHERE:
Vivian and Seymour Milstein Family Heart Center
New York, NY

Source:
Judy Romero
Cardiovascular Research Foundation

Please rate this article:
(Hover over the stars
then click to rate) Bookmark and Share

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.

All opinions are moderated before being added.

Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:






View the original article here